Neoadjuvant chemotherapy (NAC) is an effective treatment modality for patients with locally advanced breast cancer ([@bib9]; [@bib19]). Patients with operable disease may also benefit from NAC in terms of breast-conserving surgery (BCS). A certain proportion of patients receive BCS after NAC, though this varies widely according to inclusion and selection criteria ([@bib3]). According to the combined analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 and B-27 trials, the 10-year cumulative incidence of locoregional recurrence (LRR) after BCS plus breast radiotherapy (RT) was 10.3%, which was similar to that observed after mastectomy (12.3%) ([@bib13]).

Although adjuvant RT has a significant role in breast-conserving treatment ([@bib4]), it is also indicated for patients receiving BCS after NAC. It remains unclear, however, whether the addition of regional irradiation is needed. After NAC, the pathologic extent of disease is modified in 80--90% of patients, whereas pathologic complete response (CR) in both the breast and axilla was achieved in 13--26% of patients ([@bib19]). In addition, about 20--40% of patients with axillary nodal involvement at the time of diagnosis were without pathologic lymph node (LN) involvement after NAC ([@bib6]; [@bib1]). Along with age, clinical tumour characteristics before NAC, breast tumour responses after NAC, and pathologic nodal status are predictive factors for LRR after NAC ([@bib13]). In two NSABP NAC trials that previously used breast RT without regional irradiation after BCS, the LRR rate was \<10% in patients with pathologically negative LN (ypN0). Although the LRR rate was low after breast RT only, whether further benefit could be achieved from the addition of regional irradiation is unknown. According to the National Comprehensive Cancer Network (NCCN) guidelines for patients treated with NAC, adjuvant RT should be based on the worst stage pre-treatment or post-treatment tumour characteristics ([@bib15]). In contrast, a recent study compared the outcomes of patients with ypN0 after NAC plus BCS according to whether they also received regional irradiation ([@bib5]). The 5-year LRR-free survival (LRRFS) rates were 89.4% and 86.2% with and without regional irradiation, respectively, which were not significantly different from each other regardless of pre-chemotherapy tumour status.

Notably, a prospective randomised trial has not yet been conducted to address this issue. In order to gather preliminary data, the Korean Radiation Oncology Group (KROG) conducted a multicentre retrospective study to evaluate the effects of regional irradiation in patients with ypN0 after NAC followed by BCS and RT.

Materials and methods
=====================

Patients
--------

A total of 417 patients with clinical stage II--III breast cancer who achieved ypN0 after NAC followed by surgery at nine institutions in Korea between 1998 and 2009 were retrospectively identified. Patients with distant metastases, inflammatory breast cancer, involvement of supraclavicular or internal mammary LN, history of previous chemotherapy or RT or history of previous or concurrent malignancy except for thyroid cancer at the time of diagnosis were not included. Among the 417 patients, 266 underwent BCS and the remaining 151 received mastectomy. We excluded six patients who did not receive adjuvant RT after BCS. Then, 260 patients who received both BCS and RT were included in this study. The role of post-mastectomy RT for the 151 patients receiving mastectomy is described in a separate publication ([@bib21]). After approval by the KROG (KROG 12-05), the medical and RT records of the patients were retrospectively reviewed.

The median age of the 260 patients was 46 years (range, 25--72 years). According to the American Joint Committee on Cancer (AJCC) 7th edition cancer staging manual, 203 (78.1%) patients were classified as T1--2 and 57 (21.9%) patients were classified as T3--4. Clinical involvement of regional LNs was present in 251 (96.5%) patients, 50 of which were confirmed by cytologic evaluation. For the remaining 201 patients with clinical involvement of regional LNs, either ultrasonography (US; *n*=171), magnetic resonance imaging (MRI; *n*=98), or positron emission tomography (PET; *n*=140) were used for clinical diagnosis.

Molecular subtypes were classified according to the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status: luminal (ER- or PR-positive), triple-negative (ER-, PR-, and HER2-negative), or HER2 overexpressing (ER- and PR-negative, and HER2-positive).

Treatments
----------

The most common NAC regimen used in patients included in this study was anthracycline plus taxane (AT, *n*=107, 41.2%), followed by anthracycline plus cyclophosphamide (AC, *n*=72, 27.7%), and taxane only (*n*=30, 11.5%). Anti-HER2 targeted agent was administered to 24 (9.2%) patients.

All patients underwent BCS. Seven patients (2.7%) had positive resection margins, and six (2.3%) patients had close resection margin of \<1 mm. Axillary LN dissection (ALND) was performed in 236 (90.8%) patients, while the remaining 24 (9.2%) patients underwent sentinel LN biopsy (SLNB) only. The median number of sampled LNs was 15 (range, 0--42).

Adjuvant chemotherapy was delivered to 199 (76.5%) patients. The most common regimen was AT (*n*=86, 33.1%), followed by taxane only (*n*=46, 17.7%), and AC (*n*=43, 16.5%). One-hundred and three (39.6%) patients received adjuvant hormone treatment.

The RT doses delivered to the whole breast were 50.4 Gy in 28 fractions (*n*=217, 83.5%) or 50 Gy in 25 fractions (*n*=37, 14.2%). The primary tumour bed was boosted in 252 (96.9%) tumours, most commonly with 9 Gy in five fractions (*n*=109, 43.3%), followed by 10 Gy in five fractions (*n*=95, 37.7%). Elective nodal irradiation (ENI) in the supraclavicular area was performed in 136 (52.3%) patients. The decision for ENI was made individually based on institutional or physician\'s preference. There were 14 (5.4%) and 86 (33.1%) patients who received internal mammary irradiation and posterior axillary boost, respectively.

Statistical analysis
--------------------

The primary endpoint of this study was LRRFS and disease-free survival (DFS) according to ENI. The secondary endpoint was overall survival (OS) and patterns of disease recurrence according to ENI. Locoregional recurrence was defined as disease recurrence in the ipsilateral breast or ipsilateral axillary, supraclavicular, infraclavicular, or internal mammary LNs. The time from the initiation of NAC to LRR or death was defined as LRRFS. Disease-free survival was defined as the time from the initiation of NAC to relapse or death. Overall survival was defined as the time from the initiation of NAC to death from any cause.

To compare clinicopathologic characteristics according to ENI, chi-square or Fisher\'s exact tests were used. *T*-tests were used to compare continuous variables such as age and the number of sampled LNs. The LRRFS, DFS, and OS were estimated using the Kaplan--Meier method and were compared using log-rank tests. Factors that showed a probability value of \<0.2 or that were thought to be relevant were entered into a Cox proportional hazards regression analysis. A *P*-value ⩽0.05 was considered to be statistically significant, and SAS software (SAS 9.1.3; SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.

Results
=======

Patient characteristics according to ENI
----------------------------------------

Clinicopathologic characteristics according to ENI are presented in [Table 1](#tbl1){ref-type="table"}. Patients who did not receive ENI were significantly younger than patients who did receive the treatment (*P*=0.0018). Those who did not receive ENI also tended to have more advanced T classification and a triple-negative phenotype. About half (53.2%) of the patients without ENI received AT as NAC, while the regimen was administered to approximately one-third (30.2%) of patients who received ENI. As more patients received SLNB only, the number of sampled LNs was smaller in patients without ENI (median 13, range 0--42) than in patients with ENI (median 15, range 2--40) (*P*=0.0129). Pathologic CR, including ypT0 and ypTis, was achieved in 102 (39.2%) patients, which was not different between the two groups.

Failure patterns
----------------

The median follow-up duration, which was calculated from the time that NAC was initiated, was 66.2 months (range, 15.6--127.4 months). During the follow-up period, 26 (10.0%) patients experienced disease recurrence, with a median time to recurrence of 22.6 months (range, 7.9--78.2 months). Patterns of disease recurrence are shown in [Table 2](#tbl2){ref-type="table"}. Locoregional recurrence occurred in 13 (5.0%) patients, with a median latency of 25.1 months (range, 8.5--78.2 months). Among the patients who did not receive ENI, ipsilateral breast, axillary, and supraclavicular recurrences occurred in 3, 1, and 2 patients, respectively. There were no supraclavicular recurrences in patients who received ENI, whereas five and two patients experienced local and axillary recurrences, respectively. Among the patients with pathologic CR, only three (2.9%) experienced disease recurrence, two with local recurrence, and one with distant metastasis.

Survival
--------

The 5-year LRRFS, DFS, and OS for all patients were 95.5%, 90.5%, and 96.4%, respectively. Survival outcomes were not different with respect to ENI ([Figure 1](#fig1){ref-type="fig"}). Disease-free survival and OS were affected by pathologic T classification (*P*=0.0086 and 0.0012, respectively, [Figure 2](#fig2){ref-type="fig"}). In patients with pathologic CR, the 5-year LRRFS, DFS, and OS were 98.0%, 97.0%, and 100%, respectively. When the number of LNs sampled was \<13, the median number of LNs sampled in patients without ENI, DFS was significantly reduced (*P*=0.0099). When the patients were divided into subgroups according to pathologic T classification or number of sampled LNs, ENI did not affect survival outcomes in any of the subgroups (data not shown). Age, clinical T classification, molecular subtype, NAC regimen, and hormone treatment also did not affect survival outcomes ([Table 3](#tbl3){ref-type="table"}). On multivariate analysis, pathologic T classification and the number of LNs sampled of independent prognostic factors for DFS ([Table 4](#tbl4){ref-type="table"}), with hazard ratios were 2.025 (95% confidence interval (CI), 1.171--3.503; *P*=0.0116) and 0.374 (95% CI, 0.170--0.823; *P*=0.0145), respectively.

Discussion
==========

In this study, ENI did not affect survival outcomes in patients with breast cancer who achieved ypN0 after NAC followed by BCS and RT. Although clinicopathologic characteristics such as patient age, clinical T classification, and number of sampled LNs were unfavourable, whole breast irradiation alone showed outcomes that were comparable with that of ENI. As discussed by [@bib10], standard tangential field irradiation delivers substantial doses to the lower axilla ([@bib20]). Axillary coverage by whole breast irradiation, on the other hand, seems to be sufficient in terms of locoregional control in ypN0 patients after NAC followed by BCS regardless of pre-chemotherapy tumour status.

The current NCCN guidelines recommend that RT indications and fields should be based on the worst stage pre-treatment or post-treatment tumour characteristics ([@bib15]). In patients treated with NAC followed by surgery for locally advanced breast cancer, it is recommended that the RT field encompass whole breast/chest wall and ipsilateral regional LNs. This panel recommendation relies on randomised clinical trials that have shown a survival advantage for patients with axillary LN metastasis that received chest wall and regional LN RT after surgery ([@bib17]; [@bib18]), as well as retrospective studies that have shown that comprehensive RT after NAC followed by surgery benefits patients with clinical T3 or stage III--IV disease regardless of their response to NAC ([@bib11]; [@bib14]). In contrast, a recent study by [@bib5] showed no differences in treatment outcomes whether or not additional ENI was performed. The 5-year DFS and OS were 83% and 89.3% in patients who received ENI, and 85% and 94.5% in patients who did not receive ENI, respectively. That report was similar to the present study, in that a similar number of patients with ypN0 after NAC and BCS were analysed. However, in the former study, clinical characteristics such as patient age and clinical N classification were more favourable in the group that did not receive ENI compared with the group that underwent the treatment, whereas the opposite was observed in our study. Clinical node involvement at diagnosis might influence decision for ENI, as recommended by the current NCCN guidelines ([@bib15]). Along with pathologic CR, it was independently predictive of OS in the study. Additional differences between the present and former study were the median follow-up period (66 *vs* 88 months), the number of LNs dissected (15 *vs* 11), and the proportion of patients receiving primary tumour bed boost (96.9% *vs* 25.8%). The LRRFS and DFS were 95.5% and 90.5% in the present study, and 88.3% and 85.8% in the previous study, respectively. These differences may be due to variability in patient characteristics, treatment, or duration of the follow-up period. Notably, however, there were no differences in treatment outcomes according to the additional ENI in either study.

In addition to ypN0, remission of the primary tumour was achieved in 102 (39.2%) patients. This was also associated with excellent treatment outcomes regardless of ENI. Only 2.9% of the patients experienced disease recurrence, and none of the patients died during the course of the study. Also, in patients with residual tumour after NAC, omission of ENI did not worsen their treatment outcomes. This implies that ENI may not be necessary for patients with ypN0 after NAC, and that whole breast irradiation following BCS may be a feasible local treatment.

Interestingly, the number of LNs examined was associated with treatment outcomes after NAC when the cutoff number was defined as 13. There was a 9.1% difference in the 5-year DFS according to the number of LNs sampled in the present study. The prognostic significance of the number of LNs sampled in patients with LN-negative breast cancer has been well established ([@bib22]). Although small dissected LNs were counted after NAC was administered ([@bib16]), conflicting results have also been reported ([@bib2]). These studies concluded that the number of LNs sampled was not affected by NAC, and that surgeons needed to remove enough LNs to provide precise prognostic information. As ENI did not improve treatment outcomes in subgroups according to the number of LNs sampled, a small sample may potentially result in the understaging of disease. Because pathologic N classification after NAC is one of the most significant prognostic factors ([@bib13]), adequate axillary staging with sufficient LN sampling is important ([@bib2]). Although at least 10 LNs are recommended to accurately stage the axilla ([@bib15]), we used the different cutoff number defined as 13. The optimal number of sampled LNs after NAC should be further investigated to predict prognostic influence more precisely.

There were 24 (9.2%) patients that underwent SLNB only in the present study. Although a small number of LNs was examined, treatment outcomes were not inferior in those patients (data not shown). The feasibility of SLNB after NAC has been widely discussed, though it is not recommended according to the current guidelines ([@bib12]; [@bib7]). The American College of Surgeons Oncology Group Z0011 trial showed similar treatment outcomes between SLNB and ALND in patients with SLN metastasis who underwent BCS and tangential whole breast irradiation ([@bib8]). The trial did not include patients receiving NAC, and the authors noted that ALND remains a standard practice in patients with positive SLNs after NAC. Thus, future studies with negative SLNs after NAC followed by BCS and whole breast irradiation need to be conducted in order to optimise locoregional treatment strategies.

This retrospective study has several limitations. Because the data were collected from multiple institutions, chemotherapeutic regimen was heterogeneous and the decision for ENI was not based on clear guidelines. In addition, cytologic confirmation of regional LN involvement at diagnosis was performed in limited number (50 of 251) of patients. Although several imaging studies such as US, MRI, and PET were used for clinical diagnosis, potential inaccuracy in axillary staging could not be excluded. Furthermore, the numbers of patients and events do not seem to be enough to derive a definitive interpretation, including subgroup analysis.

In conclusion, whole breast irradiation without ENI may be a sufficient and feasible local treatment in patients with ypN0 breast cancer after NAC followed by BCS. Pathologic CR of the primary tumour and the number of LNs sampled were significant prognostic factors affecting DFS. To overcome the potential limitations of this retrospective analysis and to confirm the feasibility of omitting ENI in ypN0 patients after NAC for breast cancer, prospective randomised trials are warranted.
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![**LRRFS (A), DFS (B), and OS (C) according to the ENI.** No differences in treatment outcomes were observed.](bjc201426f1){#fig1}

![**LRRFS (**A**), DFS (**B**), and OS (**C**) according to pathologic T classification.** Disease-free survival and OS were significantly affected by pathologic T classification.](bjc201426f2){#fig2}

###### Clinicopathologic characteristics according to ENI

  **Characteristics**              **No ENI (*****n*****=124)**   **ENI (*****n*****=136)**   ***P***
  -------------------------------- ------------------------------ --------------------------- -----------------------------------
  Median age (years, range)        44 (23--69)                    48 (25--72)                 0.0018
  **Histologic type**                                                                         
  IDC                              115 (92.7%)                    128 (94.1%)                 0.6540
  Others                           9 (7.3%)                       8 (5.9%)                     
  **Clinical T**                                                                              
  1--2                             92 (74.2%)                     112 (82.4%)                 0.0809
  3--4                             32 (25.8%)                     24 (17.6%)                   
  **Clinical N**                                                                              
  Negative                         5 (4.0%)                       4 (2.9%)                    0.6307[a](#t1-fn2){ref-type="fn"}
  Positive                         119 (96.0%)                    132 (97.1%)                  
  **Molecular subtypes**                                                                      
  Luminal                          42 (33.9%)                     53 (39.0%)                  0.0544
  Triple-negative                  38 (30.6%)                     24 (17.6%)                   
  HER2-positive                    31 (25.0%)                     42 (30.9%)                   
  Unknown                          13 (10.5%)                     17 (12.5%)                   
  **NAC**                                                                                     
  AT                               66 (53.2%)                     41 (30.2%)                  0.0014
  AC                               27 (21.8%)                     45 (33.1%)                   
  Taxane                           9 (7.3%)                       21 (15.4%)                   
  Others                           22 (17.7%)                     29 (21.3%)                   
  **Pathological T**                                                                          
  ypT0-is                          47 (37.9%)                     55 (40.4%)                  0.1254
  ypT1                             51 (41.1%)                     65 (47.8%)                   
  ypT2-4                           26 (21.0%)                     16 (11.8%)                   
  **Axilla surgery**                                                                          
  ALND                             102 (82.3%)                    134 (98.5%)                 \<0.0001
  SLNB                             22 (17.7%)                     2 (1.5%)                     
  **Adjuvant chemotherapy**                                                                   
  AT                               58 (46.8%)                     28 (20.6%)                  \<0.0001
  AC                               11 (8.9%)                      32 (23.5%)                   
  Taxane                           12 (9.7%)                      34 (25.0%)                   
  Others                           14 (11.3%)                     10 (7.4%)                    
  No                               29 (23.4%)                     32 (23.5%)                   
  **Adjuvant hormone treatment**                                                              
  Yes                              45 (36.3%)                     58 (42.7%)                  0.2952
  No                               79 (63.7%)                     78 (57.3%)                   
  **Primary tumour bed boost**                                                                
  Yes                              119 (96.0%)                    133 (97.8%)                 0.3944
  No                               5 (4.0%)                       3 (2.2%)                     

Abbreviations: AC=anthracycline plus cyclophosphamide; ALND=axillary lymph node dissection; AT=anthracycline plus taxane; ENI=elective nodal irradiation; HER2=human epidermal growth factor receptor-2; IDC=invasive ductal carcinoma; NAC=neoadjuvant chemotherapy; SLNB=sentinel lymph node biopsy.

Fisher\'s exact test.

###### Patterns of disease recurrence according to elective nodal irradiation and pathologic T classification

  **Variables**                     ***n***   **Locoregional**   **Distant**   **Overall**
  --------------------------------- --------- ------------------ ------------- -------------
  **ENI**                                                                      
  No                                124       6 (4.8%)           10 (8.1%)     13 (10.5%)
  Yes                               136       7 (5.1%)           8 (5.9%)      13 (9.6%)
  **Pathologic T classification**                                              
  ypT0-is                           102       2 (2.0%)           1 (1.0%)      3 (2.9%)
  ypT1                              116       9 (7.8%)           12 (10.3%)    17 (14.7%)
  ypT2-4                            42        2 (4.8%)           5 (11.9%)     6 (14.3%)
  Total recurrences                 260       13 (5.0%)          18 (6.9%)     26 (10.0%)

Abbreviation: ENI=elective nodal irradiation.

###### Prognostic factors affecting survival outcomes on univariate analysis

                              **LRRFS**   **DFS**   **OS**                   
  -------------------- ----- ----------- --------- -------- -------- ------- --------
  ENI                                     0.9716             0.7328           0.6686
   No                   124     95.9%               90.2%             96.7%      
   Yes                  136     95.3%               90.9%             96.2%      
  Age                                     0.3540             0.0770           0.9058
   \<40 years           71      95.8%               87.3%             97.1%      
   ⩾40 years            189     95.5%               91.8%             96.2%      
  Clinical T                              0.5083             0.7017           0.0804
   cT1--2               203     94.8%               89.9%             95.4%      
   cT3--4               57      98.2%               92.7%             100%       
  Molecular subtype                       0.8601             0.7186           0.7447
   Luminal              95      95.4%               92.2%             97.9%      
   Triple-negative      62      96.8%               88.7%             96.8%      
   HER2-positive        73      95.7%               93.0%             95.5%      
  NAC regimen                             0.7028             0.3752           0.7439
   AT                   107     96.2%               90.6%             97.2%      
   AC                   72      97.0%               92.8%             97.1%      
   Taxane               30      92.1%               92.1%             96.7%      
   Others               51      93.8%               86.1%             93.3%      
  No. of sampled LNs                      0.1609             0.0099           0.0984
   \<13                 105     93.5%               85.0%             94.9%      
   ⩾13                  155     96.7%               94.1%             97.4%      
  Pathologic T                            0.1074             0.0086           0.0012
   ypT0-is              102     98.0%               97.0%             100%       
   ypT1                 116     93.4%               86.6%             91.9%      
   ypT2-4               42      95.2%               85.6%             100%       
  Hormone treatment                       0.8870             0.4400           0.7767
   Yes                  103     94.8%               91.8%             96.9%      
   No                   157     96.1%               89.7%             96.1%      

Abbreviations: DFS=disease-free survival; ENI=elective nodal irradiation; HER2=human epidermal growth factor receptor-2; LN=lymph node; LRRFS=locoregional recurrence-free survival; NAC=neoadjuvant chemotherapy; OS=overall survival.

###### Cox proportional hazards multivariate model for survival outcomes

                                **LRRFS**              **DFS**   **OS**                                                 
  ----------------------------- ---------------------- --------- ---------------------- -------- ---------------------- --------
  ENI                           1.187 (0.399--3.531)   0.7580    1.178 (0.543--2.560)   0.6782   1.670 (0.470--5.931)   0.4279
  Age                           --                     --        0.542 (0.250--1.175)   0.1208   --                     --
  No. of sampled LNs            0.468 (0.161--1.363)   0.1638    0.374 (0.170--0.823)   0.0145   0.336 (0.097--1.164)   0.0853
  Pathologic T classification   1.619 (0.764--3.429)   0.2085    2.025 (1.171--3.503)   0.0116   1.685 (0.710--4.001)   0.2369

Abbreviations: CI=confidence interval; DFS=disease-free survival; ENI=elective nodal irradiation; HR=hazard ratio; LN=lymph node; LRRFS=locoregional recurrence-free survival; OS=overall survival.
